[Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?]
Fiche publication
Date publication
mai 2019
Journal
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ESCHWEGE Pascal, Pr HUBERT Jacques
Tous les auteurs :
Baydaroglu E, Eschwège P, Hubert J, El Osta R
Lien Pubmed
Résumé
Phosphodiesterase type 5 inhibitors (PDE5i) are the first-line treatment of erectile dyfunction (ED). Cost of PDE5i is not covered by health insurance company in France. Few studies have examined the potential impact of the introduction of generic products of PDE5i on price non-compliance. The aim of the study was to compare the non-compliance rate because of price among patients treated for DE with generics of PDE5i and those treated with brand-name medications.
Mots clés
Adherence, Causes de dysfonction érectile, Cost, Coût, Dysfonction érectile, ED causes, Erectile dysfunction, IPDE5, Observance, PDE5 inhibitors
Référence
Prog. Urol.. 2019 May 28;: